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Abstract: Clinical treatment outcome of MRONJ (medication-related osteonecrosis of the jaw) surgery
despite radical osseous removal and primary closure healing still shows differences in terms of
outcome and disease recurrence. The study aims to assess the rate of angiogenesis of MRONJ
lesions in order to understand the impact of angiogenesis and neoangiogenesis status on MRONJ
surgical treatment outcome. This is the first study correlating microvessel density with prognosis in
MRONJ surgically-treated patients. The immunohistochemical expression of CD34 and CD105 in
MRONJ specimens obtained from surgically-treated patients was evaluated. The most vascularized
areas detected by CD34 and CD105 were selected and the microvessel density value of the samples
was registered. Samples were retrospectively divided according to the clinical outcome of MRONJ
surgical treatment, dividing patients into two groups, “healed” and “not healed”. Statistical analysis
was performed to assess if neovessels could influence treatment outcome in patients undergoing
radical surgery. In the examined cohort, this value was highly predictive of better treatment outcome
after radical surgery of MRONJ. Understanding of angiogenesis-dependent factors deserves further
attention as a future target for MRONJ prevention and therapies.
Keywords: medication-related osteonecrosis of the jaw; angiogenesis; surgical treatment; treatment
outcome
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is “an area of exposed bone or
bone that can be probed through an intra-oral or extra-oral fistula(e) in the maxillofacial
region that has persisted for more than eight weeks, with current or previous treatment
with anti-resorptive or anti-angiogenic agents and no history of radiation therapy to the
jaws or obvious metastatic disease to the jaws” [1]. Drug-induced avascular injury is a
cause for concern because of the limited therapeutic chances and there is an intellectual
gap in our understanding of the pathogenesis of this disease, moreover this condition
strongly influences the patient’s quality of life. Surgical treatment may offer benefits to
MRONJ patients [2,3], and its indications have expanded over time from being limited to
advanced stage [4,5] to being considered more effective when performed in early stage [6–9].
Nevertheless, surgery has shown different success rates in the literature, depending on
different variables which have an impact on the surgical intervention outcome [10].
Sometimes, subsequent debridements are necessary to obtain clinical healing. Success-
ful outcome has been associated with complete removal of all affected tissue to avoid the
progression of MRONJ and minimize reintervention, thus radical intent is always aimed at
first surgery.
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Evaluation of the factors affecting the necessity for revision surgery in MRONJ should
be taken into consideration to decide on the most appropriate surgical technique.
Indeed, recurrence-related factors of MRONJ are not fully elucidated [11–15]. Several
investigations have suggested that the underlying disease, the duration of administration
of MRONJ-related medications, the presence of bacterial infections as well as the adopted
treatment strategies act as factors in MRONJ recurrence [11–13]. Patients affected by os-
teoporosis are more prone to heal in comparison to cancer patients [13,14]. It appears that
this could be due to the concomitant administration of anti-cancer medications which may
play a role in the occurrence of adversity [15], although a clinical and symptomatologi-
cal remission could still be experienced by cancer patients regardless of the underlying
malignancy [16]. Concomitant treatment with corticosteroids or tobacco smoking are re-
ported to be other individual factors that can inhibit the bone healing process in MRONJ
patients [17]. A further relevant parameter that favors a positive outcome of surgery
could be the event triggering the outbreak of MRONJ [14,15]. MRONJ localization can
also affect the outcome of surgery; indeed, proximity to the maxillary sinus can lead to
interfering correlations with the condition of chronic sinusitis which would be detrimental
to healing [14]. A crucial aspect is considered the presence of a focal lesion with margins
clearly detected by the use of a TC of maxillary bones [18]. The adopted surgical technique
is reported to be one of the most relevant factors that affects the outcome of the MRONJ
treatment [15], according to the extent of the surgical procedures and the closure technique,
which strongly influences treatment outcome [11,12,19–21]. Furthermore, it has been also
reported that some intrinsic characteristics of the MRONJ lesion may result in a better or
worse outcome of the procedure. Mature bacterial biofilms are now identified as potential
critical triggers in the pathogenesis of drug-related osteonecrosis of the jaw, which can
also have a negative influence on disease resolution, as well as on its onset [22]. Thus,
the perioperative antibiotic regimen has a significant influence on the chances of disease
recurrence [23,24].
In the clinical experience of the University of Messina (Italy), despite radical surgery
and targeted antiobiotic therapy, MRONJ outcome still shows differences in terms of
outcome and disease recurrence [25,26].
Assuming that the rate of neoangiogenesis in resected bone specimen may be impli-
cated in wound healing after MRONJ surgery, this investigation was designed to determine
the prevalence of microvessels in MRONJ biopsies and to examine the relationship with
the associated perioperative outcomes.
Starting from this assumption, the immunohistochemical expression of two very reliable
markers—CD34 and CD105, effective for the study of angiogenesis and neoangiogenesis—was
evaluated in MRONJ specimens obtained from surgically-treated patients in order to understand
the impact of the angiogenesis status on MRONJ treatment outcome.
CD34 and CD105 (also known as Endoglin) are endothelial antigens that have been
chosen due to their recognized role as direct markers of the degree of vascularization
and neoangiogenesis. Specifically, CD105 is a cell membrane glycoprotein related to
newly formed blood vessels, while CD34 is expressed in both mature and newly formed
vessels [27,28].
Considering all the above-mentioned variables, the secondary objective of this study
has been to investigate the different conventional factors affecting outcome and their impact
on angiogenesis in the cohort of surgically-treated patients of the University of Messina.
2. Materials and Methods
2.1. Study Design
The study was conducted at the Department of Human Pathology of Adult and
Developmental Age of the University of Messina and coordinated from the Department of
Biomedical, Dental and Morphofunctional Imaging Sciences of the University of Messina.
The surgical specimens were obtained from surgically-treated MRONJ patients at the Center
for Treatment of the Osteonecrosis of the Jaws (University of Messina, Italy). Biopsies were
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taken from the bone tissue including the necrotic area with a rim of adjacent bone [29,30].
The necrotic tissue itself was excluded from the analysis [31]. Samples were retrospectively
divided according to the clinical outcome of MRONJ surgical treatment, dividing patients
into two groups, “healed” and “not healed”. “Healing” was defined as clinical wound
healing without dehiscence or evidence of recurrence [9,32]. Minimum follow-up was
established in at least 6 months.
2.2. Inclusion Criteria
MRONJ diagnosis had to be performed according to the definition of the Italian Soci-
eties of Oral Medicine and Maxillofacial Surgery (the SICMF-SIPMO staging system) [18,33].
Only patients who underwent radical surgery were considered eligible for the study. In
addition, patients needed to have a biopsy sample sent to the pathology lab for processing
at the time of surgery.
2.3. Surgery
Patients are referred to the Osteonecrosis of the Jaw Treatment Center, School of
Dentistry, University of Messina mostly by their oncologist. On arriving at the center,
patients are diagnosed with MRONJ based on the clinical and radiological findings in
order to distinguish focal and diffused forms. Routine procedures at first examination
include oral swab and pharmacological treatment prescription with systemic antibiotics.
Initial treatment is amoxicillin plus clavulanic acid in combination with metronidazole at
250 mg; subsequently, patients are switched to targeted antibiotic therapy on the basis of
the antibiogram result. Eight to ten weeks after the initiation of pharmacological treatment,
unchanged and progressive forms urdergo surgical treatment [34]. The systematic appli-
cation of this work flow ensures homogeneity in the patient sample in terms of antibiotic
therapy (empiric vs. targeted therapy) and time to intervention (defined as time from
MRONJ diagnosis to surgical procedure). The surgical approaches were defined according
to literature [9,10,17,23,35,36] as previously described by our study group [25,26]. The
surgery was performed in loco-regional anesthesia with intra-oral approach and consisted
in the resection of the necrotic bone until reaching bleeding vital bone. Access to the
osteonecrotic lesion was provided by a mucoperiosteal flap with total thickness sufficiently
large to include the margins of the necrotic bone. The affected bone can be removed using
ultrasonic bone surgery device. After removing the necrotic segment, if a sufficient quantity
of soft tissue to obtain closure by first intention is present, the vestibular and the lingual mu-
coperiostal flaps were directly sutured on the defect without any release incision; otherwise,
closure could be obtained using mucosal advancement flaps to allow for a tension-free
suture. Figures 1–6 show pre-surgical assessment and specimen harvesting during surgical
procedure (Figures 1–6).




Figure 1. Radiologic appearance of focal MRONJ lesion in left mandible. 
 
Figure 2. CBCT showing the necrotic bone extension. 
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Figure 3. Clinical appearance when elevating mucoperiosteal flap. 
 
Figure 4. Sub-marginal resection performed using piezoelectric device. 
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Figure 5. Intraoperative aspect. Necrotic bone segment was observed macroscopically and cut, 
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sequestrum), totally necrotic tissue (the middle part of the segment) and healthy adjacent tissue (the 
distal area of the segment). The arrow schematically indicates the portion used in this case. 
 
Figure 6. Revision of the cavity until observing bleeding bone. 
2.4. Study Variables 
Patient characteristics were analyzed. Investigated variables were patient related and 
treatment related. Demographic data (age and gender), primary disease (cancer or 
osteoporosis), type of medication (zoledronic acid, denosumab or oral bisphosphonates), 
duration of antiresorptive treatment (referring to osteoporotic vs. cancer patients and 
expressed in months) were reported and analyzed. MRONJ clinical features (localization, 
stage of MRONJ) were registered and analyzed. 
  
Figure 5. Intraoperative aspect. Necrotic bone segment was observed macroscopically and cut,
dividing it into three parts: a transitional zone (segment located in the mesial third of the sequestrum),
totally necrotic tissue (the middle part of the segment) and healthy adjacent tissue (the distal area of
the segment). The arrow schematically indicates the portion used in this case.
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Figure 6. Revision of the cavity until observing bleeding bone.
2.4. Study Variables
Patient characteristics were analyzed. Investigated variables were patient related
and treatment related. Demographic data (age and gender), primary disease (cancer or
osteoporosis), type of medication (zoledronic acid, denosumab or oral bisphosphonates),
duration of antiresorptive treatment (referring to osteoporotic vs. cancer patients and
expressed in months) were reported and analyzed. MRONJ clinical features (localization,
stage of MRONJ) were registered and analyzed.
2.5. Immunohistochemical Analysis
Histomorphometrical analyses were performed in a blinded fashion without knowl-
edge of the clinical features and treatment outcome of the patients corresponding to
individual biopsies [29]. Four micrometer-thick consecutive sections were cut from the
paraffin blocks and submitted to the immunohistochemical procedures against CD105 and
CD34. For the CD105 epitope retrieval, specimens were treated with proteinase K (S3020,
DAKO Cytomation) at room temperature for 15 min, while CD34 antigen was unmasked by
microwave oven pre-treatment in 10 mM, pH 6.0 sodium citrate buffer for 3 cycles × 5 min.
Then slides were incubated at 4 ◦C overnight with the primary monoclonal antibodies
against CD105 (DAKO Corporation, Denmark, clone SN6 h, w.d. 1:50) and CD34 (DAKO
Corporation, Denmark, clone QBEnd10, w.d. 1:50); a sheep anti-rabbit immunoglobulin
antiserum (Behring Institute; w.d. 1:25) was used and the bound primary antibody was
visualized by avidin–biotin–peroxidase revealing by the Vectastain Rabbit/Mouse Elite
Kit, according to the manufacturer’s recommendations. To reveal the immunostaining, the
sections were incubated in darkness for 10 min with 3–3′ diaminobenzidine tetra hydrochlo-
ride (Sigma Chemical Co., St. Louis, MO, USA), in the amount of 100 mg in 200 mL 0.03%
hydrogen peroxide in phosphate-buffered saline solution (PBS). Nuclear counterstaining
was performed by Mayer’s haemalum. Specificity of the procedure was confirmed by omit-
ting the primary antiserum or changing it with normal rabbit serum/phosphate buffered
saline solution (PBS pH 7.4). In addition, samples of human placenta were applied as a
positive control for CD105. The quantification of microvessels was performed according
to the procedure elsewhere described [37]. Necrotic areas were excluded. In detail, the
three most vascularized areas detected by CD105 were firstly selected (hot spots) under
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40× field. Microvessels were then counted in each of these areas under a 400× field. Single
endothelial cells or cluster of endothelial cells, with or without a lumen, were considered to
be individual vessels. The mean value of three ×400 field (0.30 mm2) counts was verified
as the microvessel density (MVD) of the slide. Successively, the MVD value was converted
into the mean number of microvessels/mm2 for statistical investigations. The vessels were
evaluated using a Nikon microscope by two independent observers blinded to the clinico-
pathological data. The same procedure was carried out for CD34 expression on equivalent
slides. Figures 7 and 8 are explanatory of the performed immuno-staining procedure. All
the remaining images have been uploaded as electronic Supplemental Material for reader
consultation (See Supplement S1 for supporting content).
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2.6. Statistical Analysis
Statistical analysis was performed to assess if neovessels could influence treatment
outcome in patients undergoing radical surgery. Data are presented as means ± standard
deviation (SD). Student’s t test for means and Fisher’s exact test (p < 0.05) for the other
values for low numbers were used to compare means between two different groups.
A p-value below 0.05 was considered statistically significant.
3. Results
Among the MRONJ cases referred to the Center for Treatment of the Osteonecrosis of
the Jaws (University of Messina, Messina, Italy), 15 patients fulfilled the above-mentioned
inclusion criteria.
3.1. Conventional Risk Factors
The characteristics of patients together with the conventional risk factors for MRONJ
recurrence are reported in Table 1.
Table 1. Study population features and conventional risk factors for MRONJ recurrence after surgical
treatment, divided according to clinical outcome.
Healed (n◦ 9) Not Healed (n◦ 6) p-Value *
Age years (average) 68.22 ± 8.45 69.17 ± 6.05 0.8166
Sex (%)
Female 7 (77.8) 1 (16.7) 0.0406
Male 2 (22.2) 5 (83.3)
Primary disease (%)
Cancer 6 (66.7) 6 0.2286
Osteoporotic 3 (33.3) /
Antiresorptive
medications (%)
Zoledronic acid 3 5 (83.33) 0.1189
Denosumab 3 1 0.6044
Oral bisphosphonate 3 /
Duration of
antiresorptive
therapy in months (SD)
Cancer patients 35.33 ± 18.79 40.33 ± 20.71 0.6356
Osteoporotic patients 72.33 ± 51.73 /
MRONJ Location (%)
Lower jaw 7 3 0.3287
Upper jaw 2 1 1.0000
Both jaws / 2
MRONJ Stage (%)
I a 1 /
I b / /
II a 4 (44.4) 1 0.5804
II b 3 (33.3) 2 1.0000
III a / /
III b 1 3 0.2352
MRONJ: medication-related osteonecrosis of the jaw. SD: standard deviation. * Student’s t test for means and
Fisher’s exact test (p < 0.5) for the other values for low numbers.
Nine patients were enrolled in the “healed” group and 6 patients in the “not healed”
group. No statistically significant difference between the “healed” (68.22 ± 8.45) vs.
the “not healed” (69.17 ± 6.05) group was registered in relation to mean age of the pa-
Int. J. Environ. Res. Public Health 2021, 18, 11362 9 of 16
tients (p-value = 0.8166). The majority of the patients in the “healed” group were women
(n = 7; 77.8%) with the remaining (n = 2; 22.2%) as male patients. In the “not healed” group,
1 (16.7%) subject was a female patient and 5 (83.3%) were male patients. The sex of the sub-
jects represented a variable that significantly influenced post-surgical healing (p = 0.0406).
In relation to primary disease, in the “healed” group there were 6 cancer patients (66.7%)
and 3 patients affected by osteoporosis (33.3%), while in the “not healed” group all the
patients had cancer. The underlying pathology had not a statistical significant impact
on healing (p = 0.2286). Among patients enrolled in the “healed” group, 3 patients were
treated with zoledronic acid, 3 patients received denosumab and 3 patients were exposed
to oral bisphosphonates, while in the “not healed” group almost all the patients received
zoledronic acid (n = 5; 83.33%) with denosumab being administered to the remainig patient
(n = 1). The type of antiresorptive medication was not significanty related to healing since
no difference in the use of zoledronic acid (p = 0.1189) or denosumab (p = 0.6044) has been
observed. In relation to the duration of therapy, this information has been stratified on
the basis of the clinical indication of the administered medication (cancer vs. osteoporosis)
and expressed in months. Cancer patients in the “healed” group received anti-resorptive
treatment (35.33 ± 18.79) for a shorter period of time than cancer patients in the “not healed”
group (40.33 ± 20.71). Median duration of anti-resorptive treatment in patients affected
by osteoporosis was calculated only for the “healed” group (72.22 ± 51.73 months) as all
the patients healed. Duration of antiresorptive therapy was not statistically related to a
better outcome of surgical treatment (p = 0.6356). The most common location of MRONJ
was the mandible in both “healed” (n = 7) and “not healed” (n = 3) groups, with the upper
jaw being affected in n = 2 patients in the “healed” and 1 patient in the “not healed” group.
In two cases of the “not healed” group, both jaws were affected. MRONJ location was not
significantly related to post-surgical healing in lower (p = 0.3287) or upper jaw (p = 1.0000).
According to the SIPMO classification, the most frequent stage of MRONJ in the “healed”
group was stage IIa (n = 4; 44.4%) followed by stage IIb (n = 3; 33.3%). The remaining
2 patients were stage Ia (n = 1) and IIIb (n = 1). In the “not healed” group, there was a higher
proportion of stage IIIb (n = 3; 50%) patients followed by stage IIb (n = 2; 33.3%) and IIa
(n = 1; 16.67%). In this case, series MRONJ stage did not affect surgical treatment outcome.
3.2. CD34 and CD105 Expression
Fifteen MRONJ tissue samples were evaluated. Table 2 shows the immunohistochemi-
cal expression of the angiogenetic factors evaluated.
Table 2. Immunohistochemical parameters in patients with MRONJ divided according to treatment outcome.
Healed (n◦ 9) Not Healed (n◦ 6) t-Value p-Value
CD34 MVD (v/mm2)—median rate 66.57 3.94 −2.33203 0.015756
CD105 MVD (v/mm2)—median rate 19.33 0 −3.59139 0.000973
MVD = microvessel density.
Angiogenesis as expressed by the median CD34 rate was higher in the “healed”
group (MVD = 66.57) compared with “not healed” patients (MVD = 3.94). This difference
in angiogenesis was significant between the two groups (p = 0.015756). Newly formed
angiogenesis-related capillaries, which stained positively for CD105, were detected only in
the specimens of “healed” patients (MDV = 19.33). The inhibition of neoangiogenesis was
strongly significantly related to surgical treatment outcome (p = 0.000973).
3.3. Correlation between CD34 and CD105 Expression and Conventional Risk Factors
The possible relationship between patient’s characteristics and angiogenesis is exam-
ined in Table 3.
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Female 8 / 0.0256 6 2 0.1319
Male 3 4 2 5
Primary disease (%)
Cancer 8 4 0.5165 6 6 1.0000
Osteoporotic 3 / 2 1
Antiresorptive medications (%)
Zoledronic acid 5 3 0.5692 3 5 0.3147
Denosumab 3 1 1.0000 3 1 0.5692
Oral bisphosphonate 3 / 2 1 1.0000
Duration of antiresorptive
therapy in months
≤24 months 5 1 0.6044 4 2 0.6084
>24 months 6 3 4 5
MRONJ Location (%)
Lower jaw 2 1 1.0000 1 2 0.5692
Upper jaw 9 1 0.0769 7 3 0.1189
Both jaws / 2 / 2
MRONJ Stage (%)
I a 1 / 1 /
I b / / / /
II a 5 / 3 2 1.0000
II b 3 2 0.5604 3 2 1.0000
III a / / / /
III b 2 2 0.5165 1 3 0.2821
MRONJ: medication-related osteonecrosis of the jaw. SD: standard deviation. * Student’s t test for means and Fisher’s exact test (p < 0.5) for
the other values for low numbers.
Pertaining to the correlation between angiogenetic biomarkers and conventional risk
factors in the observed samples, sex was significantly related to the presence of CD34
stained capillaries (p = 0.0256) although it was shown to be uninfluential to the expression
of CD105 (p = 0.1319). Primary disease didn’t affect vascularization (p = 0.5165) nor neoan-
giogenesis (p = 1.0000). The different administration of zoledronic acid in the “healed”
(p = 0.5692) vs. the “not healed” (p = 0.3147) as well as the assumption of denosumab in the
“healed” (p = 1.0000) vs. the “not healed” (p = 0.5692) groups was not statistically significant.
The duration of the anti-resorptive therapy itself appeared to be unrelated to the vascular-
ization of the jaw bone and the neovessels formation (p = 0.6084). In relation to MRONJ
location, the upper jaw was significantly related to a greater angiogenesis (p = 0.0769). In
this analysis, the MRONJ lesions divided in the three SIPMO stages didn’t show a statistical
difference in the local expression of the investigated angiogenetic biomarkers.
Table 4 summarizes the anti-cancer therapies undertaken in order to explore the
concomitant use of antiangiogenic agents that can affect the investigated parameters.
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1 70/male Prostate Degarelix
2 68/male Myeloma Bortezomib + Melphalan; Daratumumab; Lenalidomide + Dexamethasone
3 79/male Prostate Enantone + 22RaCl
4 72/male Myeloma Lenalidomide
5 63/female Breast Fulvestrant Palbociclib Letrozolo
6 63/male Renal cell Sunitinib; Everolimus; Sorafenib
7 60/male Prostate Bicalutamide; Abiraterone acetate
8 59/female Breast
Tamoxifen, Letrozole, Lapatinib, Fulvestrant, Exemestane, Docetaxel, Capecitabine,
Vinorelbine, Cyclophosphamide, Methotrexate, Eribulin, Doxorubicin, Palbociclib +
Fulvestrant, Fluorouracil (5-FU)
9 67/female Breast Everolimus; Paclitaxel; Exemestane; Doxorubicin; Anastrozole; Eribulin
10 72/male Breast Cyclophosphamide + Methotrexate
11 80/female Breast Everolimus + Exemestane
12 79/female Myeloma Lenalidomide + Dexamethasone; Bortezomib + Melphalan + Prednisolone
4. Discussion
The response of clinically-similar MRONJ lesions to the same surgical treatment may
be vastly different. Therefore, to improve clinical care and to give an optimal treatment,
recurrence-related factors must be identified.
The aim of the present study was to investigate the role of altered angiogenesis and
its potential relationship with wound healing in MRONJ surgery starting from the con-
sideration that angiogenesis is a critical component of MRONJ development and may be
implicated in wound healing [31]. Indeed, the hypothesis that the impairment/inhibition of
angiogenesis has an important role in the development and maintenance of MRONJ seems
to be the most relevant pathogenetic theory explaining the pathway in which necrosis
occurs [38,39]. It involves avascular necrosis through VEGF and PECAM-1 suppression
confirming the interplay between angiogenesis and osteogenesis in bone integrity main-
tenance [40,41]. The few studies published on the topic have mostly been restricted to
the comparison between MRONJ vs. health subjects [42]. According to Gao et al., the
suppression of angiogenesis and osteogenesis (identified by a reduction in CD31 in MRONJ
models) could be significant in the potential mechanism of MRONJ itself [43]. The results
by Wehrhan et al. showed that the capillary area related to CD31-associated vascularity
was slightly reduced in the MRONJ-related specimens compared to normal mucoperiosteal
tissue, likewise the newly-formed angiogenesis-related capillaries which were positively
stained for CD105, were detected to a lesser extent in MRONJ-related specimens than in
mucoperiosteal tissue not exposed to bisphosphonates [31]. Compromised angiogenesis
would most likely be involved in post-surgical healing, although other aspects of the
vasculature (e.g., blood flow) could contribute to MRONJ [44,45]. The results of the present
study showed a greater number of newly-formed angiogenesis-related capillaries detected
by CD105 staining in tissue belonging to healed MRONJ patients (p = 0.000973) and a
higher expression of CD34 (p = 0.015756), indicating that inhibition of angiogenesis could
be implicated in MRONJ healing.
Patients with non-healable wounds are expected to have a lower microvessel density
associated with lower success rate than those who have a higher microvessel density and a
major healing potential.
Microvessel count, reflecting the angiogenesis, appears to be deserving of further
study. Further prospective studies are necessary to investigate these findings systematically;
nevertheless, a significant trend emerged in the presented results and could be of interest.
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The present study also addresses the conventional factors affecting MRONJ recurrence
and their correlation with the immunohistochemical parameters expression. There are
several variables that have a statistically significant impact on MRONJ post-surgical healing:
gender, patients’ underlying pathologies, anti-resorptive drugs used, time to treatment,
MRONJ stage and others [11,12,23].
Almost none of the conventional factors taken into consideration (age, type of med-
ication, duration of antiresorptive therapy, underlying pathology, MRONJ location and
MRONJ stage) were significantly related to MRONJ surgical treatment outcome with the
exception of sex. This data is considered to be due to the prevalence of women in the
examined cohort (68%) reflecting the fact that MRONJ-related medications are mostly
prescribed for post-menopausal osteoporosis and breast cancer. Although in this analysis
the underlying pathology and the type of antiresorptive medication had not a statistical
significance, it is noteworthy that all patients with osteoporosis assuming oral bispho-
sphonates completely healed after surgery. This is consistent with Martins et al., who
observed significant differences in outcomes and time to healing according to primary
disease (p < 0.05) [46].
Data from the literature confirm the importance of primary disease on the outcome of
the therapy; indeed, cancer patients treated with high-potency bisphosphonates may expe-
rience a poor treatment outcome in comparison to denosumab-related MRONJ, likewise
patients with prolonged bone anti-resorptive therapy may show a worse outcome [13,14].
In relation to MRONJ location, the upper jaw was significantly related to a greater
angiogenesis (p = 0.0769) but this didn’t translate into a better surgical outcome. This may
be due to the anatomical differences between the maxillary and mandibular bones and
owing to the intimate anatomical relationship with the sinus [47–49]. Patients attributable
to the three stages of the disease were treated, with a higher frequency of cases attributable
to stage II. It has been reported that early stage treated with radical surgery showed a
better treatment outcome [50]. Nevertheless, the MRONJ stage did not play a significant
role in the incidence of surgical failure (p = 0.2352), in this case series. Analysis of the
correlation between neoangiogenetic biomarkers and conventional risk factors showed that
the presence of CD34 stained capillaries was significantly correlated with sex and MRONJ
location. MVD as assessed by CD34 and CD105 expression was significantly associated
to surgical treatment outcome. Comparison was very difficult to perform because of the
limited size of the study samples. Nevertheless, within this group of selected patients
we found that some markers of angiogenesis were useful tools to characterize patient’s
surgical healing and were associated with disease outcome. However, consideration should
be given to concomitant anti-cancer therapies (Table 4) since the use of antiangiogenic
agents can affect the investigated parameters, contributing to angiogenesis inhibition,
microenviroment alterations and immune response [51–54]. Our results highlight the need
for a wider and more reliable investigation on neoangiogenesis biomarkers in MRONJ.
There are certain limitations to our study. For one, we had limitation in sample size,
which may have limited the disclosure of statistically significant relationships between
MVD and MRONJ surgical treatment outcomes. We had enrolled all patients who un-
derwent surgery for MRONJ in our Department during a four-year period starting from
the year 2016; however, recruitment experienced a severe decline during the COVID-19
pandemic, now slowly returning to normal volumes. We chose to recruit only patients
treated with radical intent to avoid bias resulting from different prognoses of palliative
treatment. Moreover, according to the SICMF-SIPMO diagnostic criterion for MRONJ are
clinical and radiological [34,35], thus the clinical routine of our Center biopsy of MRONJ
specimens is not performed systematically. Therefore, during the study period, a total of
77 MRONJ patients were enrolled and a total of 34 surgical procedures were performed
with radical intent. Among these, 15 patients met the inclusion criteria. However, it must
also be said that single-center studies related to the surgical treatment of MRONJ always
present limited data and the cohorts presented in literature are generally small. Anyhow, it
must be recognized that the small sample size limited the interpretation of any significant
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clinical impacts; for this reason, future development of the research aims to expand the
patient cohort with progressive patient recruitment.
At the time of writing, follow-ups range from a minimum of 6 months to a maximum
of 6 years; when expanding our cohort, it is our intention to take in consideration not only
failures but recurrences also which may occur in a different location. Nevertheless, despite
the limited sample, we were able to demonstrate a significant impact of the expression of
CD34 and CD105 on MRONJ outcome.
5. Conclusions
This is the first study correlating MVD with prognosis in MRONJ surgically-treated
patients. In the examined cohort, the MDV as assessed by CD34 and the presence of
neovessels by CD105 was highly predictive of better treatment outcome after radical
surgery of MRONJ. Exploring CD34 and CD105 expression in MRONJ surgically-treated
patients’ specimens revealed that the healing potential of patients could be also influenced
by the presence of neovessels in the MRONJ lesion. To identify diagnostic markers of
drug-induced vascular injury would add value in MRONJ risk management and prog-
nosis [55,56]. The implication on clinical practice of having such information available
would be important to schedule surgery, post-operative wound management and follow-up
examinations on the basis of the success/failure risk. Furthermore, since tooth extraction
is the major precipitating event in MRONJ, investigating the role of altered angiogenesis
in wound healing may have future implications in MRONJ prevention as well as in the
surgical treatment. Finally, we believe that the understanding of angiogenesis-dependent
factors deserves further attention as a future target for MRONJ therapies. Indeed, on
the basis of these results, a potential protection of the jaw from the negative influence of
zoledronic acid and/or denosumab by locally enhancing angiogenesis could be imagined
for MRONJ prevention and treatment.
Our research group is presently investigating the expression of several angiogenetic
markers on a wider sample of MRONJ patients and controls to provide a better definition
of their potential clinical value; and in the field of the biotechnology, we aim at the devel-
opment of new treatment strategy adjuvants or alternatives to surgical treatment for all
non-eligible patients for whom only palliative therapies are currently available.
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